Some prominent biotech companies tend to capture the majority of investors’ and analysts’ attention compared to their industry peers. aTyr Pharma (ATYR), a small-cap, clinical-stage biotech, doesn’t belong to that group.
However, the drugmaker has performed well this year; its shares are up 40% year to date. What’s more, aTyr Pharma could have even more upside in the (very) near future. Is the stock a good investment at this time? Let’s find out.
This post originally appeared at The Motley Fool.